European Journal of Gastroenterology & Hepatology最新文献_第3页

Nourishing remission: the role of Crohn's disease exclusion diet and partial enteral nutrition in pregnancy: a comprehensive review. 营养缓解：克罗恩病排除饮食和部分肠内营养在妊娠中的作用：全面回顾。

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-10-01 Epub Date: 2025-07-22 DOI: 10.1097/MEG.0000000000003050

Sara Micallef, Franziska Mintoff, Pierre Ellul, Martina Sciberras

{"title":"Nourishing remission: the role of Crohn's disease exclusion diet and partial enteral nutrition in pregnancy: a comprehensive review.","authors":"Sara Micallef, Franziska Mintoff, Pierre Ellul, Martina Sciberras","doi":"10.1097/MEG.0000000000003050","DOIUrl":"10.1097/MEG.0000000000003050","url":null,"abstract":"The management of Crohn's disease during pregnancy presents significant challenges. Active Crohn's disease can be treated with corticosteroids or biologics. While these treatments are generally considered safe during pregnancy, they are not without potential side effects, leading to patient hesitancy in initiating therapy despite guidance from inflammatory bowel disease specialists. We present the case of a 34-year-old woman who was diagnosed with Crohn's disease 3 weeks before getting pregnant and who opted not to use medication during her pregnancy. For the initial 26-28 weeks, she received conservative treatment. Following a deterioration in her symptoms and an increase in calprotectin levels, she commenced the Crohn's disease exclusion diet (CDED) combined with partial enteral nutrition (PEN). This led to significant symptomatic improvement and a decrease in faecal calprotectin levels. At 40 weeks of gestation, she gave birth to a healthy baby. This case underscores the potential efficacy of CDED and PEN as dietary management strategies for Crohn's disease even during pregnancy, although further research is warranted to compare these approaches with conventional treatments. In addition, it emphasises the critical role of preconception counselling regarding medication safety and effective disease management during pregnancy.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1180-1185"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of hepatitis C virus infection and associated determinants among men who have sex with men without HIV in Amsterdam, the Netherlands, between 2012 and 2021. 2012年至2021年荷兰阿姆斯特丹无艾滋病毒男男性行为者中丙型肝炎病毒感染发生率及相关决定因素

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-10-01 Epub Date: 2025-06-23 DOI: 10.1097/MEG.0000000000003008

Kris Hage, Jeffrey Koole, Anders Boyd, Amy Matser, Udi Davidovich, Margreet Bakker, Lia van der Hoek, Jelle Koopsen, Sjoerd Rebers, Janke Schinkel, Maria Prins

{"title":"Incidence of hepatitis C virus infection and associated determinants among men who have sex with men without HIV in Amsterdam, the Netherlands, between 2012 and 2021.","authors":"Kris Hage, Jeffrey Koole, Anders Boyd, Amy Matser, Udi Davidovich, Margreet Bakker, Lia van der Hoek, Jelle Koopsen, Sjoerd Rebers, Janke Schinkel, Maria Prins","doi":"10.1097/MEG.0000000000003008","DOIUrl":"10.1097/MEG.0000000000003008","url":null,"abstract":"Objective: To assess the hepatitis C virus (HCV) prevalence, incidence, and associated determinants among men who have sex with men (MSM) without HIV in Amsterdam, the Netherlands.Methods: We used data from the Amsterdam Cohort Studies (2012-2021) to calculate the prevalence of past/current HCV infection at the first study visit and incidence rate of primary HCV infection during follow-up. We identified determinants associated with incident HCV infection using univariable Bayesian exponential survival models. Phylogenetic analysis was conducted to compare HCV sequences of MSM without HIV to those from MSM with HIV and those using HIV pre-exposure prophylaxis.Results: A total of 926 MSM were included. At first visit, 2/926 (0.2%) had a past/current HCV infection. Among 891 participants contributing to 6083.30 person-years of follow-up, three incident HCV infections were observed (incidence rate = 0.05/100 person-years). These infections were observed between 2014 and 2018, and all participants had never used HIV pre-exposure prophylaxis. Incident infections were associated with receptive condomless anal sex, having 1-10 sexual partners vs. none, recent injecting drug use (IDU), ever IDU, and fisting, albeit there was substantial uncertainty for all determinants (i.e. 95% credible intervals included one). Phylogenetic analysis revealed that one HCV-RNA sequence was closely related to HCV sequences from MSM with HIV.Conclusion: While HCV infection is uncommon among MSM without HIV, the risk of infection seems to increase among those with specific behaviors. HCV screening for MSM without HIV should be focused on those reporting these behaviors.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1173-1179"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the impact of sarcopenia on chronic pancreatitis outcomes: a U.S. population-based study. 了解肌肉减少症对慢性胰腺炎结局的影响：一项基于美国人群的研究。

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-10-01 Epub Date: 2025-05-19 DOI: 10.1097/MEG.0000000000003006

Anmol Singh, Tanisha Sehgal, Jasraj Kahlon, Ritika Dhruve, Aalam Sohal, Anjali Shah, Divyesh Sejpal

{"title":"Understanding the impact of sarcopenia on chronic pancreatitis outcomes: a U.S. population-based study.","authors":"Anmol Singh, Tanisha Sehgal, Jasraj Kahlon, Ritika Dhruve, Aalam Sohal, Anjali Shah, Divyesh Sejpal","doi":"10.1097/MEG.0000000000003006","DOIUrl":"10.1097/MEG.0000000000003006","url":null,"abstract":"Objectives: Sarcopenia, characterized by the loss of skeletal muscle mass and function, is increasingly recognized as a critical factor influencing clinical outcomes in patients with chronic pancreatitis (CP). This study aims to evaluate the prevalence, hospitalization burden, and survival outcomes associated with sarcopenia in CP patients.Methods: We used the National Inpatient Sample 2016-2020 to identify patients with CP and stratified them into two groups based on the presence of sarcopenia. Data were collected on patient demographics, hospital characteristics, and comorbidities. The outcomes assessed were inhospital mortality, sepsis, shock, acute kidney injury, and resource utilization. Multivariate regression analysis was used to assess the relationship between sarcopenia and clinical outcomes.Results: Of the included patients, 18.3% (165 900) had sarcopenia. Patients with sarcopenia had higher odds of inhospital mortality [adjusted odds ratio (aOR): 3.29, 95% confidence interval (CI): 3.06-3.54, P < 0.001], sepsis (aOR: 1.58, 95% CI: 1.49-1.69, P < 0.001), acute kidney injury (aOR: 1.46, 95% CI: 1.42-1.51, P < 0.001), and ICU admission (aOR: 2.6, 95% CI: 2.47-2.74, P < 0.001). Sarcopenic patients also had longer hospital stays (+3.87 days, P < 0.001) and increased hospitalization costs (+$40 285.15, P < 0.001).Conclusions: Sarcopenia is a strong, independent predictor of adverse clinical outcomes in CP patients, including increased mortality and healthcare costs. Early detection and management through nutritional and rehabilitative interventions should be integral components of CP care.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1122-1126"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The safety and efficacy of rituximab in autoimmune hepatitis: a systematic review and quality assessment. 利妥昔单抗治疗自身免疫性肝炎的安全性和有效性：系统评价和质量评价。

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-10-01 Epub Date: 2025-05-06 DOI: 10.1097/MEG.0000000000002981

Mohammad Amin Habibi, Fatemeh Aghayee, Mohammad Sina Mirjani, Mohammad Reza Karimifar, Mohammad Reza Ahmadi, Seyed Mohammad Eazi, Poriya Minaee, Mohammad Reza Pashaei, Ahmad Hormati, Mohammad Mahdi Akbari Aleagha, Sajjad Ahmadpour

{"title":"The safety and efficacy of rituximab in autoimmune hepatitis: a systematic review and quality assessment.","authors":"Mohammad Amin Habibi, Fatemeh Aghayee, Mohammad Sina Mirjani, Mohammad Reza Karimifar, Mohammad Reza Ahmadi, Seyed Mohammad Eazi, Poriya Minaee, Mohammad Reza Pashaei, Ahmad Hormati, Mohammad Mahdi Akbari Aleagha, Sajjad Ahmadpour","doi":"10.1097/MEG.0000000000002981","DOIUrl":"10.1097/MEG.0000000000002981","url":null,"abstract":"Up now, several medications were proposed for the treatment of autoimmune hepatitis (AIH); however, because of the unclear pathophysiology of AIH, the most optimal treatment option needs to be elucidated. This systematic review sought to investigate the safety and efficacy of rituxiamb (RTX) in patients with AIH. A total of 27 studies were included in the present study. A total of 80 patients had the eligibility criteria, of which the majority of them were female (63 female and 17 male). Of the 80 patients, nine patients were pediatrics. The induction of remission and maintenance therapy were the most common indications for RTX in AIH. Of the 80 patients, we found complete remission in 55% of patients ( n = 44) and partial remission in 11% of patients ( n = 11). Of the nine pediatric patients, we found complete remission in 77% of patients ( n = 7) and partial remission in 22% of patients ( n = 2). Unclear response was also reported in 31% of patients ( n = 25), which included four studies. 375 mg/m 2 × 4 followed by 1000 mg × 2 was the most commonly applied RTX dosage used for treatment of AIH. RTX therapy was associated with infectious complications in six patients; however, one episode of cancer, death, mild conjunctivitis, and large bowel perforation were also reported. RTX is an anti-CD20 mAb and was shown to be effective for the treatment of AIH, but there is no consensus regarding the therapeutic role of RTX in AIH.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1097-1109"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of chest X-ray in latent tuberculosis infection screening for inflammatory bowel disease patients in low-incidence countries: in response to Gatt et al. (Eur J Gastroenterol Hepatol 2025;37:728-732). 胸部x线检查在低发病率国家炎症性肠病患者潜伏性结核感染筛查中的作用：响应Gatt等人的研究[J] . Gastroenterol hepatology, 2025;37:728-732]。

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-10-01 Epub Date: 2025-08-27 DOI: 10.1097/MEG.0000000000003035

Trixi Braasch, Britta Siegmund

引用次数: 0

Application of insulin resistance score in type 2 diabetes mellitus complicated with fatty liver and liver fibrosis. 胰岛素抵抗评分在2型糖尿病合并脂肪肝及肝纤维化中的应用。

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-10-01 Epub Date: 2025-05-06 DOI: 10.1097/MEG.0000000000002998

Shaojie Duan, Mengdie Chen, Jie Chen, Yaojian Shao, Xiaolong Jin, Chaohui Wang, Ping Feng, Xiaosheng Teng, Zhenjun Yu

{"title":"Application of insulin resistance score in type 2 diabetes mellitus complicated with fatty liver and liver fibrosis.","authors":"Shaojie Duan, Mengdie Chen, Jie Chen, Yaojian Shao, Xiaolong Jin, Chaohui Wang, Ping Feng, Xiaosheng Teng, Zhenjun Yu","doi":"10.1097/MEG.0000000000002998","DOIUrl":"10.1097/MEG.0000000000002998","url":null,"abstract":"Background: Insulin resistance plays a pivotal role in the progression of type 2 diabetes mellitus (T2DM). An in-depth investigation into the role of insulin resistance scores in evaluating T2DM combined with metabolic-associated fatty liver disease (MAFLD) and liver fibrosis holds significant importance for clinical decisions and personalized treatment.Methods: The study screened patients with diabetes from Taizhou Central Hospital from June 2020 to May 2024. In conjunction with the National Health and Nutrition Examination Survey (NHANES) database, various statistical methods such as logistic regression analysis, restricted cubic spline, and receiver operating characteristic curves were employed to complete data analysis.Results: This study encompassed 3776 patients with T2DM, including 1074 diagnosed with MAFLD. Insulin resistance scores in the MAFLD group were significantly elevated. Compared with nonfibrotic patients, those with T2DM and liver fibrosis exhibited notably higher Chinese visceral adiposity index (CVAI) scores and notably lower triglyceride-glucose index and visceral adiposity index scores; the incidence of hypertension, coronary heart disease, stroke, and peripheral arterial disease were significantly elevated. Among other insulin resistance scores, the CVAI score demonstrated the highest value for correlating with the MAFLD and liver fibrosis in patients with T2DM. The NHANES database, encompassing data from 6763 individuals, validated the aforementioned findings, further affirming that the CVAI score exhibited optimal consistency with the risk of T2DM with MAFLD and liver fibrosis.Conclusion: The insulin resistance scores were significantly elevated in T2DM combined with MAFLD. The CVAI score demonstrated the best predictive effect on MAFLD and liver fibrosis.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1155-1165"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complement C3 predicting acute-on-chronic liver failure in cirrhotic patients with bacterial infection within 90 days: a cohort study. 补体C3预测90天内合并细菌感染的肝硬化患者的急性慢性肝功能衰竭：一项队列研究

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-10-01 Epub Date: 2025-08-27 DOI: 10.1097/MEG.0000000000002991

Shuling Chen, Ruiqi Li, Hongli Liu, Xiaoning Feng, Hui Zhou, Wenquan Zeng, Hao Ren, Qingfang Xiong, Caiyun Zhang, Xixuan Wang, Yongfeng Yang

{"title":"Complement C3 predicting acute-on-chronic liver failure in cirrhotic patients with bacterial infection within 90 days: a cohort study.","authors":"Shuling Chen, Ruiqi Li, Hongli Liu, Xiaoning Feng, Hui Zhou, Wenquan Zeng, Hao Ren, Qingfang Xiong, Caiyun Zhang, Xixuan Wang, Yongfeng Yang","doi":"10.1097/MEG.0000000000002991","DOIUrl":"10.1097/MEG.0000000000002991","url":null,"abstract":"Objective: Cirrhotic patients with bacterial infections (BI) face high risks of acute-on-chronic liver failure (ACLF) and mortality. This study assessed the diagnostic value of serum complement component 3 (C3) for predicting 90-day ACLF and mortality in this population.Methods: We prospectively analyzed clinical data from 105 cirrhotic patients with BI (mean age 57.2 ± 11.6 years; 57 male) admitted to the Second Hospital of Nanjing between September 2023 and March 2024. Primary outcomes were ACLF development and mortality within 90 days.Results: Thirty-one patients (29.5%) developed ACLF within 90 days. Lower C3 levels independently predicted both ACLF [hazard ratio (HR): 0.14, 95% confidence interval (CI): 0.02-0.93; P = 0.04) and mortality (HR: 0.10, 95% CI: 0.00-0.89; P = 0.01). Time-dependent receiver operating characteristic analysis showed C3 predicted ACLF with AUROCs of 0.76 (30 day), 0.73 (60 day), and 0.72 (90 day). For mortality, areas under the time-dependent receiver operating characteristic curves (AUROCs) were 0.76 (30 day), 0.69 (60 day), and 0.68 (90 day). A cutoff of 0.66 g/L was established using etiology-adjusted restricted cubic spline. C3 correction improved the predictive AUROCs of Child-Turcotte-Pugh, Model of End-Stage Liver Disease, and the Chronic Liver Failure Consortium Acute Decompensation scores for mortality (all P > 0.05). Random forest regression identified C3 among the top 10 risk factors for ACLF development.Conclusion: Serum C3 demonstrates significant prognostic value as a predictor for 90-day ACLF and mortality in cirrhotic patients with bacterial infections, offering potential clinical utility in risk stratification.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1147-1154"},"PeriodicalIF":1.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Presence of alarm symptoms at coeliac disease diagnosis is not associated with poorer long-term treatment outcomes. 乳糜泻诊断时出现报警症状与较差的长期治疗结果无关。

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-09-22 DOI: 10.1097/MEG.0000000000003073

Eneli Katunin, Camilla Pasternack, Kalle Kurppa, Teea Salmi, Heini Huhtala, Katri Kaukinen, Rakel Nurmi

{"title":"Presence of alarm symptoms at coeliac disease diagnosis is not associated with poorer long-term treatment outcomes.","authors":"Eneli Katunin, Camilla Pasternack, Kalle Kurppa, Teea Salmi, Heini Huhtala, Katri Kaukinen, Rakel Nurmi","doi":"10.1097/MEG.0000000000003073","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003073","url":null,"abstract":"Objectives: Alarm symptoms at coeliac disease (CeD) diagnosis predict a more severe disease presentation, but the long-term implications remain unclear. We studied the prevalence of alarm symptoms at diagnosis and their association with outcomes.Methods: A mixed-method cohort study combined retrospective medical record review with data collection through patient interviews and blood sampling from 814 adult patients with CeD after a median of 9.7 years on a gluten-free diet (GFD). Validated questionnaires assessed symptoms and quality of life. Alarm symptoms included anaemia, weight loss, dysphagia, vomiting, melaena, and rectal bleeding. Patients were grouped by the presence or absence of alarm symptoms.Results: 45% of the patients presented with alarm symptoms, primarily (95%) anaemia and weight loss. These patients were significantly more often female (83 vs. 71%; P < 0.001), had more severe clinical presentation (P < 0.001; reported severe symptoms 41 vs. 2%) and more advanced mucosal damage (P < 0.001; subtotal or total villous atrophy 72 vs. 57%) than those without these symptoms. On GFD, these patients experienced fewer persistent symptoms (asymptomatic 71 vs. 79%; P = 0.035) but more often had osteopenia/osteoporosis (15 vs. 9%; P = 0.008). The groups did not differ in the strictness of GFD, positivity of CeD autoantibodies, quality of life, fractures, or other comorbidities.Conclusion: Alarm symptoms were common at CeD diagnosis. After 9.7 years on a GFD, patients with alarm symptoms had a higher incidence of osteopenia/osteoporosis, but generally did not demonstrate poorer long-term outcomes compared to those without alarm symptoms.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature. 异位肝组织引起的肝细胞癌：文献的系统回顾。

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-09-19 DOI: 10.1097/MEG.0000000000003069

Sami Akbulut, Tevfik Tolga Sahin

{"title":"Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature.","authors":"Sami Akbulut, Tevfik Tolga Sahin","doi":"10.1097/MEG.0000000000003069","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003069","url":null,"abstract":"Ectopic liver tissue (ELT) is a rare congenital anomaly characterized by hepatic parenchyma located outside the native liver. In this systematic review, 55 cases of hepatocellular carcinoma (HCC) arising from ELT were identified through a literature search performed in PubMed, MEDLINE, Scopus, and Web of Science, in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420251084866). The median age was 61 years (IQR: 52-68), and 65.5% were male. Hepatitis B and C were present in 26.5% cases. The most common tumor locations were the subphrenic (n = 11), peritoneal (n = 7), retroperitoneal (n = 6), and pancreatic (n = 6) regions. Solitary tumors were reported in 78.2% of cases, with a median tumor size of 71 mm (IQR: 36.5-100). AFP was elevated in 74.4% of patients, and AFP-L3 (100%) and PIVKA-II (72.7%) were elevated in most tested cases. Immunohistochemistry frequently showed positivity for HepPar-1 (88.6%), glypican-3 (81.3%), and arginase-1 (87.5%). Surgical resection was the primary treatment modality, and in addition, transarterial chemoembolization, tyrosine kinase inhibitors, and immune checkpoint inhibitors have been used as therapeutic options. The median follow-up was 17 months (IQR: 12-36), during which 85.4% of patients were alive. Distant metastasis occurred in 18.6% of cases, and local recurrence in 6.7%. In conclusion, ectopic HCC is a rare tumor entity with variable clinical presentations. Despite limited classical risk factors, surgical resection remains associated with a favorable prognosis. Histopathological confirmation is essential for diagnosis, and multimodal treatment strategies should be considered for advanced disease.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mild liver function decline in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma: a real-world study. 阿特唑单抗和贝伐单抗治疗肝细胞癌患者的轻度肝功能下降：一项真实世界的研究

IF 1.8 4区医学

European Journal of Gastroenterology & Hepatology Pub Date : 2025-09-17 DOI: 10.1097/MEG.0000000000003075

Victoria Delhoume, Paul Girot, Marion Khaldi, Juliette Boilève, Maëva Salimon, Yann Touchefeu

{"title":"Mild liver function decline in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma: a real-world study.","authors":"Victoria Delhoume, Paul Girot, Marion Khaldi, Juliette Boilève, Maëva Salimon, Yann Touchefeu","doi":"10.1097/MEG.0000000000003075","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003075","url":null,"abstract":"Background: Atezolizumab plus bevacizumab is recommended as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic significance of early mild liver function deterioration in a real-world cohort.Methods: This retrospective study included patients with HCC treated with atezolizumab plus bevacizumab as first-line between September 2020 and January 2024. We evaluated the evolution of liver function during the first 6 months of treatment, survival, and adverse events, and the impact of mild deterioration [change in albumin-bilirubin (ALBI) grade, without clinical ascites, encephalopathy, jaundice, or gastrointestinal bleeding] on overall survival (OS).Results: Among 155 patients, 44 had a Child-Pugh score ⩾ B7, and 111 had ALBI grade ⩾ 2 at baseline. Median OS was 24.1 months. There was a significant deterioration in the ALBI score at cycle 2 (P = 0.001), 3 (P = 0.001), and 4 (P = 0.015), with no deterioration in the subsequent treatment. In multivariate analyses, baseline ALBI grade 3 (vs. 1), Eastern Cooperative Oncology Group 1 (vs. 0), macrovascular invasion, but not mild deterioration of liver function, were identified as independent prognostic predictors for OS.Conclusion: Early mild liver function deterioration does not impact OS during first-line treatment with atezolizumab and bevacizumab.","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0